- Home
- SID vs AGIO Comparison
SID vs AGIO Comparison
Compare SID & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SID
- AGIO
- Stock Information
- Founded
- SID 1941
- AGIO 2007
- Country
- SID Brazil
- AGIO United States
- Employees
- SID N/A
- AGIO N/A
- Industry
- SID Steel/Iron Ore
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- SID Industrials
- AGIO Health Care
- Exchange
- SID Nasdaq
- AGIO Nasdaq
- Market Cap
- SID 2.3B
- AGIO 2.4B
- IPO Year
- SID 1997
- AGIO 2013
- Fundamental
- Price
- SID $1.54
- AGIO $35.42
- Analyst Decision
- SID Sell
- AGIO Buy
- Analyst Count
- SID 2
- AGIO 7
- Target Price
- SID $2.95
- AGIO $56.33
- AVG Volume (30 Days)
- SID 2.7M
- AGIO 1.1M
- Earning Date
- SID 11-12-2024
- AGIO 02-13-2025
- Dividend Yield
- SID 19.03%
- AGIO N/A
- EPS Growth
- SID N/A
- AGIO N/A
- EPS
- SID N/A
- AGIO 11.80
- Revenue
- SID $8,019,254,042.00
- AGIO $32,871,000.00
- Revenue This Year
- SID N/A
- AGIO $33.38
- Revenue Next Year
- SID $1.48
- AGIO $163.06
- P/E Ratio
- SID N/A
- AGIO $3.00
- Revenue Growth
- SID N/A
- AGIO 36.79
- 52 Week Low
- SID $1.50
- AGIO $20.96
- 52 Week High
- SID $4.03
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- SID 26.68
- AGIO 28.75
- Support Level
- SID $1.50
- AGIO $37.20
- Resistance Level
- SID $1.97
- AGIO $44.46
- Average True Range (ATR)
- SID 0.08
- AGIO 4.27
- MACD
- SID -0.03
- AGIO -2.06
- Stochastic Oscillator
- SID 7.29
- AGIO 1.06
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. The company operate throughout the entire steel production chain, from the mining of iron ore to the production and sale of a diversified range of steel products. It operates in five segments namely, Steel, Mining, Logistics, Energy, and Cement. It generates maximum revenue from the steel segment. Geographically, it derives a majority of revenue from Asia.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.